Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. is undergoing a significant acquisition involving the issuance of shares and cash payment to purchase assets, specifically in the functional sugar alcohol sector, which is experiencing steady market growth and consolidation [1][2]. Group 1: Market Overview - The functional sugar alcohol market in China has shown steady growth, with the market size reaching approximately 10.2 billion yuan in 2022 and projected to grow to 21 billion yuan by 2027, indicating substantial growth potential [5]. - The global functional sugar alcohol market was estimated at 4.6 billion USD in 2022, with expectations to reach 7.7 billion USD by 2030, reflecting a compound annual growth rate (CAGR) of about 6.7% [5]. - The xylitol market in China has also been expanding, with the global market projected to grow from 1.12 billion USD in 2024 to 1.64 billion USD by 2029, at a CAGR of 7.9% [7]. Group 2: Company Position and Strategy - Huakang and the target company are leading players in the xylitol production sector, with significant market shares and competitive advantages in production capacity and technology [4][11]. - The acquisition aims to consolidate Huakang's position in the domestic and international xylitol market, enhancing operational efficiency and resource integration across supply chains, production, and sales channels [11][13]. - The target company has a production capacity of 20,000 tons of xylitol, and Huakang has a capacity of 35,000 tons, positioning both companies as major suppliers in the industry [9][10]. Group 3: Financial Aspects of the Transaction - The total cash consideration for the acquisition is 366 million yuan, to be paid in two installments: 244 million yuan within 30 days post-registration and 122 million yuan within 30 days after the first payment's one-year anniversary [19][20]. - The cash payment structure is designed to ensure transaction certainty while alleviating short-term cash flow pressures for Huakang, allowing for better financial management [20][22]. - The acquisition is expected to generate goodwill of approximately 46.71 million yuan, with the total goodwill post-transaction reaching 813.30 million yuan, representing 20.54% of Huakang's net assets [23].

司向不特定对象发行可转换公司 债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【71】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客 观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经授权 ...

浙江华康药业股份有限公司 关于公司部分募集资金投资项目结项并将该项目节余募集资 金永久补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华康药业股份有限公司（以下简称"公司"或"华康股份"）于 2025 年 2 月 26 日召开第六届董事会第二十九次会议和第六届监事会第十八次会议，审议 通过了《关于公司部分募集资金投资项目结项并将该项目节余募集资金永久补充 流动资金的议案》，公司首次公开发行股票募投项目"年产 3 万吨 D-木糖绿色智 能化提升改造项目"和"年产 3 万吨高纯度结晶赤藓糖醇建设项目"已达到预定 可使用状态，公司拟对上述项目进行结项，并将节余募集资金永久补充流动资金， 本议案尚需提请股东大会审议。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准浙江华康药业股份有限公司首次公开 发行股票的批复》（证监许可[2020]3152 号）核准并经上海证券交易所同意，公 司首次公开发行人民币普通股 A 股股票 2,914 万股，每股发行价格为人民币 51.63 元， ...